Download Library
Title |
Abstract | Posted |
Size |
|---|---|---|---|
| Application Note: Evaluation Of PARP Inhibitors: Performed On BMG LABTECH’s FLUOstar Omega | Poly ADP-ribosylation is a post-translational modification of proteins that plays a crucial role in regulating DNA repair. Poly (ADP-ribose) polymerase (PARP) transfers ADP-ribose to itself and other nuclear proteins such as histones. The substrate for that reaction is NAD+. By BMG LABTECH, GmbH | 07/01/2009 | 230.5 KB |
| White Paper: Research Efficiency In Hard Times: It’s Time To Adapt | Nobody likes hard times, but they do have one redeeming quality: They focus attention on areas neglected in good times. The need for greater efficiency is a prime example, especially for small drug development companies. Even in the best of times, they must cope with the formidable combination of high costs, long timelines, and low success rates. And when hard times come, they feel it first and most acutely. These companies should be the first to ask: Is there a better way? By Michael Rosenberg, M.D., MPH, Life Science Leader magazine | 06/23/2009 | 65.6 KB |
| Case Study: Guilty Or Not Guilty: Justice Is Served With XP205 Semi-Microbalance | The independent Forensic Scientific Service (FND) of the State Police in St. Gallen, Switzerland conducts analytical and forensic tests with the aim of detecting proof of suspected crimes such as the illegal possession of drugs. As samples are generally available in powder form and in rather small quantities, an XP205 semi-microbalance was the customer’s solution to assist in their delicate weighing tasks. By Mettler-Toledo, Inc. | 06/16/2009 | 92.2 KB |
| Datasheet: Biologics Manufacturing | Abbott offers you state-of-the-art Biologics Manufacturing Capabilities, including Smart solutions to process design, analytical characterization and cGMP manufacturing, supporting the development and commercialization of your biopharmaceutical product. | 06/11/2009 | 52.9 KB |
| Datasheet: Mustang® Q XT Ion Exchange Chromatography Capsules | Mustang Q XT capsules have been designed for optimum membrane chromatography performance, providing scalability from process development through to full scale manufacturing. | 05/22/2009 | 125.7 KB |
| Datasheet: Q And S HyperCel™ Chromatography Sorbents | Q and S HyperCel sorbents are composed of a rigid cellulose matrix that has excellent flow properties and generates low backpressure, compatible with the needs of large-scale protein production. | 05/22/2009 | 643.1 KB |
| Realize Your Cytotoxic Agent’s Unique Potential | Product Brochure: Cytotoxic Manufacturing | 05/18/2009 | 480.1 KB |
| Add A Powerful Ingredient To Your Parenteral Manufacturing | Product Brochure: Parenteral Manufacturing | 05/18/2009 | 9.02 MB |
| Flyer: About PYRAMID Laboratories | PYRAMID Laboratories, Inc. (PYRAMID), established in 1988, is located in southern California, USA. Our facilities are housed in three (3) buildings covering over 50,000 sq. ft. | 05/13/2009 | 16.8 KB |
| SCYNEXIS Capabilities Overview | SCYNEXIS, Inc. is a premier drug discovery and development company delivering effective and innovative drug pipeline solutions to human and animal health pharmaceutical and global health partners. | 05/13/2009 | 1.86 MB |
| Flyer: Pharmaceutical Development Services | The scientific staff at PYRAMID Laboratories, Inc. has more than 30 years of experience across all areas of parenteral formulation and manufacturing. From pre-clinical through clinical and on to commercial manufacturing, PYRAMID focuses on optimizing your product’s stability and performance. | 05/13/2009 | 18.0 KB |
| Flyer: PYRAMID Laboratories Lyophilization Services | PYRAMID’s goal in the development of a lyophilized drug product is to produce a pharmaceutically elegant and physico-chemically stable product that can be easily reconstituted and administered to the patient. Scientists at PYRAMID have the background and knowledge in lyophilization technology to assist you in reaching that goal for your drug product. | 05/13/2009 | 15.8 KB |
| Article: Managing Solid Waste From Single- Use Systems In Biopharmaceutical Manufacturing | The increasing implementation of single-use systems (SUS) in biopharmaceutical manufacturing has been driven by multiple factors including cost reduction, increased flexibility, improved process development time, and reduced capital investment. By Hélène Pora and Bruce Rawlings | 03/31/2009 | 229.0 KB |
| Article: Implementing Single-Use Technology In Biopharmaceutical Manufacturing | In biopharmaceutical manufacturing, single-use components and systems can offer distinct advantages over reusable, cleanable systems. Deciding whether to move to a single-use approach, however, depends on many factors. By Weibing Ding and Jerold Martin | 03/31/2009 | 317.0 KB |
| Article: A Prescriptive Approach To Management Of Solid Waste From Single-Use Systems | In biopharmaceutical manufacturing, the disposal of solid waste from single-use systems is becoming an increasingly important issue. The new focus is driven by several major factors including a broadening range of disposable technologies enabling, in some cases, the installation of completely disposable multistage systems; improved scalability of singleuse components offering production capacities to thousands of liters; and the environmental impact of waste disposal. By Bruce Rawlings and Hélène Pora | 03/31/2009 | 459.3 KB |
| Article: Environmental Impact of Single-Use And Reusable Bioprocess Systems | Bioprocess manufacturing systems have incorporated single-use/disposable components for more than 50 years and have demonstrated welldefined process benefits from their use (1–6). The environmental impact of single-use technologies, however, has been a major focus of attention only in recent years. By Bruce Rawlings and Hélène Pora | 03/31/2009 | 720.7 KB |
| Brochure: Research Capabilities - HEOS Software Suite | HEOS® suite is a comprehensive web-based Drug Research information management software that supports geographically distributed scientists and facilitate collaboration. The complex process of transforming a hit into a clinical candidate involves data generated by a broad range of sources. The success of the project relies on the capability of the partners to easily, securely and efficiently access, share and communicate the right information at the right time. HEOS® is a web portal that provides a secure and user-friendly data handling system. It allows all the involved collaborators to view results and make informed decisions. | 03/30/2009 | 907.4 KB |
| Brochure: Research Capabilities - Medicinal Chemistry | The complex process of transforming a hit into a clinical candidate requires a broad range of technical skills and capabilities. SCYNEXIS incorporates Medicinal Chemistry, Computational Chemistry, Analytical Chemistry and Bioanalytical Chemistry into SCYNEXIS Research Teams that focus these disciplines to meet specific project demands. SCYNEXIS supports these efforts with a secure and chemist-friendly data handling system that allows both SCYNEXIS and customer scientists to view results and make informed decisions. | 03/30/2009 | 258.8 KB |
| Brochure: SCYNEXIS Overview | In today’s rapidly changing pharmaceutical environment, there is a necessity for world-class research and development that is available when you need it. | 03/29/2009 | 379.3 KB |
| Datasheet: 4.6.8 Promise™ | The 4.6.8 Promise™ ensures that Patheon will have your projects completed in the fastest possible timeframe, without compromising the high standards of work you demand. | 02/04/2009 | 794.7 KB |
| Datasheet: Quick To Clinic™ | Utilizing Patheon’s network of specialized development centers throughout North America and Europe, the Quick to Clinic™ program allows for rapid provision of clinical trial materials for First Time in Human (phase I) studies. | 02/04/2009 | 1.13 MB |
| Datasheet: Quick to Market™ | Quick To Market™ is a unique Patheon-only program that offers accelerated transfer of commercially available products from an existing manufacturing plant to a plant within Patheon’s network. | 02/04/2009 | 878.2 KB |
| EUDRAPULSE® | EUDRAPULSE® enables rapid, immediate (pulsed) drug release after a defined lag time. A layer composed of drug and organic acid, or its salt, is applied to a core acting as the carrier, which is coated with EUDRAGIT® RL/ RS. | 12/30/2008 | 429.5 KB |
| EUDRACOL® | EUDRACOL® gives Pharma Polymers a multi-unit technology that provides targeted drug delivery direct to the colon, with delayed and uniform drug release. The system consists of several layers. At the center is a core containing the active. | 12/30/2008 | 614.0 KB |
| EUDRAGIT® Power Through Flexibility | Add flexibility and power to your development process with EUDRAGIT® polymers.Our wide range of immediate, enteric and sustained release polymers allows you to design any number of combinations to match your targeted release profile. | 12/29/2008 | 2.88 MB |